These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 11547843

  • 1. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH.
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 3. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES, Lyles KW, Singer FR, Meunier PJ.
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [Abstract] [Full Text] [Related]

  • 4. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE, Lobaugh B, Lyles KW.
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [Abstract] [Full Text] [Related]

  • 5. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 6. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
    Price RI, Gutteridge DH, Stuckey BG, Kent GN, Retallack RW, Prince RL, Bhagat CI, Johnston CA, Nicholson GC, Stewart GO.
    J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
    O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA.
    J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD, Retallack RW, Fenton AJ, Grill V, Gutteridge DH, Kent GN, Prince RL, Worth GK.
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonate resistance in Paget's disease of bone.
    Joshua F, Epstein M, Major G.
    Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA.
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.
    Ferraz-de-Souza B, Martin RM, Correa PH.
    J Bone Miner Metab; 2013 May; 31(3):360-5. PubMed ID: 23076294
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.